Autonomix Medical Reports New Topline Results From First 15 Patients' 7-Day Data Highlighting Significant Impact On Treatment Of Pancreatic Cancer Pain with Maintained Pain Reduction; 79% Responder Rate Achieved With Zero Opioid Use And Quality Of Life Improvement At 7 Days Post-Procedure; Clinically Meaningful Mean Of 4.96 Or 63% Reduction Of Pain On The VAS Pain Scale Was Observed
Portfolio Pulse from Benzinga Newsdesk
Autonomix Medical, Inc. (NASDAQ:AMIX) reported positive preliminary results from its clinical trial on treating pancreatic cancer pain. The trial showed a 79% responder rate with significant pain reduction and no opioid use, improving patients' quality of life.
October 31, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Autonomix Medical's trial results show a 79% responder rate in reducing pancreatic cancer pain without opioids, potentially boosting investor confidence and stock price.
The trial results are significant as they demonstrate a high responder rate and pain reduction without opioid use, which is a major advancement in treatment. This could lead to increased investor confidence and a positive impact on AMIX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100